Beovu, a New Therapy for AMD, Funded for Use in Two Provinces
Wednesday, March 23 2022 | 08 h 02 min | Vision Science
Novartis announced in December that a new anti-VEGF injection brolucizumab (brand name Beovu) is now funded by the Ontario and New Brunswick Drug Plans for treatment of wet age-related macular degeneration (AMD). Anti-VEGF injections are the standard of care for wet AMD, helping prevent further vision loss and in some cases restore some vision. Beovu is a new anti-VEGF that allows patients to delay the time between injections.
After the first few doses, eligible patients can be put on a once every three month treatment schedule. Novartis will be working with other provinces to increase access to this treatment for more Canadians.